TFMG
4 years ago
$AMRH | #AmeriHoldings Bullish Setup
Ameri Holdings , Inc. is a technology services company, which specializes in systems, applications, and products (SAP) cloud, digital, and enterprise services. It offers technology consulting; business intelligence; cloud services; application development, integration, and maintenance; implementation services; infrastructure services; and independent validation services. The company was founded by Srinidhi Devanur in February 1994 and is headquartered in Suwanee, GA.
stock1ace1
4 years ago
3 Mill o/s Pending Deal Closing ~>
Pending Transaction With Jay Pharma Inc. ATLANTA , July 1, 2020 /PRNewswire/ -- AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri" or the "Company"), announced that the Company is continuing to work through the regulatory review process towards finalizing the proposed amalgamation transaction with Jay Pharma, Inc. ("Jay Pharma"),
whytestocks
4 years ago
News: $AMRH Ameri Holdings Provides Update On Pending Transaction With Jay Pharma Inc.
ATLANTA , July 1, 2020 /PRNewswire/ -- AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri" or the "Company"), announced that the Company is continuing to work through the regulatory review process towards finalizing the proposed amalgamation transaction with Jay Pharma, Inc. ("Jay Pharma"),...
In case you are interested AMRH - Ameri Holdings Provides Update On Pending Transaction With Jay Pharma Inc.
Hawkeye_tt
4 years ago
AMERI Holdings Amalgamation Partner Jay Pharma Reports IRB Approval For Testing Proprietary CBD Formulation In Brain Cancer
June 02 2020 - 09:00AM
PR Newswire (US) Print
ATLANTA, June 2, 2020 /PRNewswire/ -- AMERI Holdings, Inc. (NASDAQ: AMRH) (the "Company"), today announced that its proposed amalgamation partner Jay Pharma Inc. ("Jay Pharma") received institutional review board ("IRB") approval by Rabin Medical Center in Petah Tikva, Israel for a Phase I/II clinical trial investigating Jay Pharma's proprietary cannabidiol ("CBD") formulation for the treatment of glioblastoma multiforme ("GBM"), a rare and aggressive form of brain cancer. This open-label, two-arm, randomized, prospective study is scheduled to commence following final approval from the Israel Ministry of Health, which is expected this summer.
Hawkeye_tt
4 years ago
CC announced....yep, explain this to us...
AMERI Holdings, Inc. (NASDAQ: AMRH) (โAmeriโ), will host a conference call and webcast at 4:15 p.m. ET on Thursday, January 16, 2020, to discuss its entry into an amalgamation agreement (the โtransactionโ) announced today whereby the shareholders of Jay Pharma will become the majority holders of Ameriโs outstanding stock.
Hawkeye_tt
4 years ago
So much for the IT part.....
In connection with the Amalgamation, Ameri will spin-off its existing IT services business to a private entity founded by Ameri management in partnership with Ameriโs current Series A Preferred Equity Holders (the โSpin-Off,โ and collectively, with the Amalgamation, the โTransactionsโ). The Transactions are expected to close in the first half of 2020, subject to Ameri shareholder approval, approval of the Nasdaq Stock Market, and other customary closing conditions.
Hawkeye_tt
4 years ago
AMERI Holdings, Inc. (NASDAQ: AMRH) (โAmeriโ) today announced it entered into an amalgamation agreement (the โAmalgamation Agreementโ) with Jay Pharma Inc. (โJay Pharmaโ), a Canadian company dedicated to developing innovative, evidence-based cannabinoid products and combination therapies to address unmet needs in cancer care, pursuant to which the shareholders of Jay Pharma will become the majority holders of Ameriโs outstanding stock by way of an amalgamation (the โAmalgamationโ). In connection with the Amalgamation, Ameri will spin-off its existing IT services business to a private entity founded by Ameri management in partnership with Ameriโs current Series A Preferred Equity Holders (the โSpin-Off,โ and collectively, with the Amalgamation, the โTransactionsโ). The Transactions are expected to close in the first half of 2020, subject to Ameri shareholder approval, approval of the Nasdaq Stock Market, and other customary closing conditions.
โWe are excited about the Jay Pharma business and believe that it is a great opportunity that will maximize shareholder value,โ said Dev Nidhi, Executive Chairman of Ameri.
On a pro forma basis and based upon the number of shares of Ameri common stock to be issued in the Amalgamation, current Ameri shareholders will own approximately 16% of the combined company and current Jay Pharma shareholders will own approximately 84% of the combined company. The Boards of Directors of both Ameri and Jay Pharma have unanimously approved the transaction.
Jay Pharma is primarily focused on developing over-the-counter cannabinoid-based palliative and wellness products to address the side effects of cancer and cancer treatment, including skin reactions, pain, nausea, and anxiety. Jay Pharma holds the exclusive rights to Israel-based Tikun Olam Ltd.โs (โTikun Olamโ) proprietary cannabinoid genetics and data for oncology, including for the development of over-the-counter and pharmaceutical products. Tikun Olam has amassed one of the worldโs largest patient treatment databases in the field of medical cannabis, with over 20,000 patient records noting strains used and symptoms treated. Use of Tikun Olam strains were analyzed in 2,970 cancer patients seeking assistance with sleep problems, pain, nausea, and lack of appetite (Bar-lev Schleider, Eur J Intern Med, 2018); treatment was found to be a well-tolerated, effective, and safe option to help patients cope with the malignancy related symptoms. Jay Pharma plans to bring leading oncology clinicians and researchers, together with academic and industry partners to enhance clinically proven products to patients. In addition, Jay Pharma has an experienced management team led by Dave Johnson who will assume the Chairman & CEO role upon the closing of the Transactions.